REFERENCES
- Wijermans P. W., Gerrits W. B. J., Haak H. L. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292–296
- Anolik J. H., Friedberg J. W., Zheng B., et al. B Cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2006, in press
- Anolik J., Barnard J., Cappione A., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis & Rheumatism 2004; 50: 3580–3590
- McLaughlin P., Grillo-Lopez A. J., Link B., et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. J Clin Oncol 1998; 16: 2825–2833
- Alachkar H., et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immuno 2006; 120: 310–318
- Ko J., et al. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immuno 2005; 116: 37–41
- Czuczman M. S., Koryzna A., Mohr A., et al. Rituximab in Combination with Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. J Clin Oncol 2005; 23: 694–704
- Cabanillas F., Liboy I., Pavia O., et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17: 1424–1427
- Hochster H. S., Weller E., Ryan T., et al. 2004; 6502, Results of E1496: A Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) JCO, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement)
- Friedberg J. W., Huang J., Dillon H., et al. Initial therapeutic strategy in follicular lymphoma: An analysis from the National LymphoCare Study. J Clin Oncol (supplement) 2006; 24: 428s
- Friedberg J. W. Potential long term toxicities should impact choice of therapy for indolent non-Hodgkin's lymphoma. Hematologica 2006; 91: 1453–1455